Levetiracetam
Product Images NDC 60432-831

11 FDA label images from Morton Grove Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 60432-831). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Morton Grove Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Total Daily Dose (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 01)

Total Daily Dose (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 01)
A formula panel displaying the equation to calculate total daily dose (mL/day) for Levetiracetam. It shows the daily dose in mg/kg multiplied by patient weight (kg), divided by 100 mg/mL concentration to yield the total daily dose in milliliters per day.*
FDA Label Image

Creatinine Clearance (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 02)

Creatinine Clearance (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 02)
A mathematical formula for calculating creatinine clearance (CLcr) based on patient age in years, weight in kilograms, and serum creatinine in mg/dL, including an adjustment factor of 0.85 for female patients. The formula is presented as part of pharmacokinetic or dosing guidance.*
FDA Label Image

Creatinine Clearance For Bsa (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 03)

Creatinine Clearance For Bsa (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 03)
A chemical structure diagram depicting the molecular arrangement of the active ingredient Levetiracetam.*
FDA Label Image

Image 01 (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 04)

Image 01 (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 04)
Chemical structure of levetiracetam, showing a pyrrolidone ring attached to an ethyl group and an amide group on a central carbon.*
FDA Label Image

Image 02 (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 05)

Image 02 (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 05)
A bar chart comparing the percentage of patients for three groups: Placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%). The x-axis shows the treatment groups with patient counts (Placebo N=95, Levetiracetam 1000 mg/day N=97, Levetiracetam 3000 mg/day N=101), and the y-axis represents the percentage of patients ranging from 0% to 45%.*
FDA Label Image

Image 03 (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 06)

Image 03 (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 06)
A vertical bar graph comparing the percentage of patients across three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). Patient numbers for each group are indicated: Placebo (N=111), Levetiracetam 1000 mg/day (N=106), and Levetiracetam 2000 mg/day (N=105). The y-axis shows the percentage of patients from 0% to 45%.*
FDA Label Image

Image 04 (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 07)

Image 04 (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 07)
A bar chart comparing the percentage of patients showing a response in two groups: Placebo (N=104) at 14.4% and Levetiracetam 3000 mg/day (N=180) at 39.4%. The chart includes patient counts and percentage values for each group.*
FDA Label Image

Image 05 (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 08)

Image 05 (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 08)
A vertical bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The Y-axis represents the percentage of patients from 0% to 45%. The placebo group (N=97) shows 19.6%, and the Levetiracetam group (N=101) shows 44.6%, with asterisk marking significance for the Levetiracetam bar.*
FDA Label Image

Omage 06 (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 09)

Omage 06 (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 09)
Bar chart comparing the percentage of patients between a placebo group (51 patients) and a Levetiracetam group (58 patients). The placebo group shows 19.6% of patients, while the Levetiracetam group shows a higher value at 43.1%. The chart indicates a notable difference favoring Levetiracetam.*
FDA Label Image

Image 07 (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 10)

Image 07 (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 10)
A bar chart comparing the percentage of patients between two groups: Placebo and Levetiracetam. The placebo group (N=84) shows 45.2% patients, while the Levetiracetam group (N=79) shows 72.2% patients. The y-axis represents the percentage of patients from 0% to 100%.*
FDA Label Image

Levetiracetam Oral Solution Label (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 11)

Levetiracetam Oral Solution Label (27944da6 Ecc6 4d33 90c3 1f9519cbc5fe 11)
Label for Levetiracetam oral solution 100 mg/mL by Morton Grove Pharmaceuticals, Inc., with NDC 60432-831-16. The bottle contains 16 fl oz (473 mL) and is labeled for prescription use only. The label includes storage instructions, pharmacist dispensing guidance, and warnings to keep out of reach of children, along with tamper-evident seal instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.